Preamble
The rapid development of techniques and tools in neurointervention has broadened the indications for treatment and enabled us to take charge of more patients than previously possible. This evolution has occurred thanks to co-operation between physicians and companies. This is a positive process and as long as such a development is directed at improving patients' lives at an acceptable cost it should be fully supported.
There are, however, some negative aspects to such a rapid progress, and to the relationships that develop between companies and physicians. Because of the rapid progress in neurointervention new devices may not be sufficiently tested when introduced into daily practice. A conflict of interest will arise when a physician has a significant financial or other personal interest in a device or a company.
There should ideally be a complete financial separation between physicians and companies guaranteeing product use based only on merit. Physicians may be influenced by payment for consultancy or proctoring services. This may be justified for the work performed. However, excessive payment can constitute a strong conflict of interest.
Companies have exerted influence on scientific meetings through funding. Companies covering the costs of a physician to attend a meeting incur a subtle obligation.
Countries have different regulatory frameworks regarding the use of new drugs and devices. There are varying models of funding health care around the world complicating the formulation of guidelines for these issues. These real and potential problems are the reasons the WFITN has decided to propose guidelines regarding relations between industry, scientific societies and physicians.
-Guidelines for physicians
Physicians should avoid any conflict of interest in their role as decision-makers in the use of drugs, devices and equipment. Where financial or other support has been accepted from companies this should be acknowledged where appropriate, for example during academic meetings, when submitting publications, to health administrators, professional authorities, institutional research and ethics committees.
Sponsorship by companies for fellowship training or attending meetings should wherever possible be done through independent or-• Companies may market their products at meetings, for example at company seminar presentations, but these should be separate from the scientific program.
Social events
• Social events are an integral part of the scientific meeting and cannot be specifically funded by a company. • The sponsorship money should be allocated by the organizers of the meeting according to the budget.
-Research
• All research has to comply with the WMA Helsinki declaration of 1964 with updates.
• Clinical trials and registries can only be supervised by independent professional medical organizations or independent physicians. • Companies can fund trials and registries but to avoid any conflict of interest or influence on the integrity of the results expressed by the clinical research, a company cannot interfere with or supervise them. • Results, negative and positive, should always be published. ganizations such as teaching institutions or scientific organisations and at all times the laws of the applicable country must be respected. Direct sponsorship of individuals should be avoided. The sponsorship of activities not directly related to medical education is not acceptable.
-Role of companies
• Training: Companies may fund the training of doctors at recognised teaching institutions, according to WFITN criteria 1,2 .
• Any training course structured by companies alone cannot be recognised as a part of training in neurointervention.
• Diplomas or certificates of competency issued by a company are not recognised by the WFITN.
• Continuing medical education credits cannot be issued for device-related training or company arranged seminars.
-Events at scientific meetings
• It is the task of the scientific committee to select speakers for the scientific component of meetings.
